ANGLE announces second assay with AstraZeneca as it deepens relationship with pharma giant
–News Direct– ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with details of a supplier agreement with AstraZeneca PLC to develop an androgen receptor (AR) detection assay to enhance prostate cancer studies. With a contract value of 550,000, the project is scheduled for completion in the first quarter of next year. Newland said…